Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

BACKGROUND: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). METHODS: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Omid, Robert, Caroline, Ribas, Antoni, Hodi, F. Stephen, Walpole, Euan, Daud, Adil, Arance, Ana S., Brown, Ewan, Hoeller, Christoph, Mortier, Laurent, Schachter, Jacob, Long, Jianmin, Ebbinghaus, Scot, Ibrahim, Nageatte, Butler, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173747/
https://www.ncbi.nlm.nih.gov/pubmed/30202085
http://dx.doi.org/10.1038/s41416-018-0207-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173747/
https://www.ncbi.nlm.nih.gov/pubmed/30202085
http://dx.doi.org/10.1038/s41416-018-0207-6

Ejemplares similares